Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accounts Payables (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Accounts Payables for 10 consecutive years, with $27.3 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 27.85% to $27.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.3 million through Dec 2025, down 27.85% year-over-year, with the annual reading at $27.3 million for FY2025, 27.85% down from the prior year.
  • Accounts Payables hit $27.3 million in Q4 2025 for Rocket Pharmaceuticals, down from $28.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $45.8 million in Q4 2023 to a low of $17.9 million in Q2 2021.
  • Historically, Accounts Payables has averaged $30.2 million across 5 years, with a median of $30.4 million in 2023.
  • Biggest YoY gain for Accounts Payables was 86.9% in 2022; the steepest drop was 39.61% in 2022.
  • Year by year, Accounts Payables stood at $19.6 million in 2021, then surged by 86.9% to $36.7 million in 2022, then increased by 24.9% to $45.8 million in 2023, then fell by 17.39% to $37.8 million in 2024, then fell by 27.85% to $27.3 million in 2025.
  • Business Quant data shows Accounts Payables for RCKT at $27.3 million in Q4 2025, $28.3 million in Q3 2025, and $40.5 million in Q2 2025.